Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ELCC 2018 Media Alert: Fighting Number-one Cancer Killer With Research and A Multidisciplinary Approach

20 Mar 2018
Lung and other thoracic tumours

GENEVA, Switzerland – Around 2,300 participants from across the world will meet in Geneva at the eighth European Lung Cancer Congress (ELCC 2018, 11-14 April 2018) to learn about and discuss the latest research results in the field of lung cancers.

Organised by ESMO (European Society for Medical Oncology) and the IASLC (International Association for the Study of Lung Cancer), along with their partner societies ESTRO (European Society for Radiotherapy & Oncology) and ETOP (European Thoracic Oncology Platform), the ELCC Congress brings together some of the most important organisations in the field of thoracic oncology.

Key themes and programme highlights

  • Immunotherapy: which line of treatment, combinations, biomarkers and mechanisms of resistance.
  • Optimisation of targeted therapy in lung cancer
  • First-line treatment of oncogene and non-oncogene addicted tumours
  • New perspectives in the treatment of SCLC and mesothelioma including novel targets and an overview of the past, present, and future prospects for chemotherapy, radiotherapy and immunotherapy
  • Latest advances in surgery and radiation therapy of lung cancer
  • Implementation of lung cancer screening
  • Molecular background of lung cancer and biomarkers of NSCLC
  • Controversial topics: using off-label targeted agents for uncommon driver alterations; T790M: Liquid biopsy or histological samples?; Next generation TKI: front-line or later?

More than 220 studies will be shared with the audience in different formats (oral presentation, poster discussion or poster presentation) and published as a supplement of the Journal of Thoracic Oncology, IASLC’s official scientific journal.

Internationally renowned experts will give inspiring lectures which promise to reveal new insights into topical issues.

The full Congress programme is available here.

Media is invited to join the leading thoracic oncology experts as they gather for state-of-the-art education and the latest advances in lung cancer treatment.

ELCC 2018 Press programme

The following press releases will be issued:

  • “Further evidence that immunotherapy provides a long-term survival benefit for lung cancer patients” – Abstract 136PD_PR - 3-year survival and duration of response in randomized Phase II study of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC (POPLAR) - Julien Mazières et al., under embargo until Thursday, 12 April 2018 at 07:45 CEST (Central European Summer Time)
  • “Alectinib provides longer symptom improvement than crizotinib in ALK-positive lung cancer” – Abstract 138PD_PR - Patient-reported outcomes (PROs) in ALEX: a phase III study of alectinib (ALEC) vs crizotinib (CRIZ) in non-small-cell lung cancer (NSCLC) - Maurice Pérol et al., under embargo until Thursday, 12 April 2018 at 07:45 CEST (Central European Summer Time)
  • “Coordinating nurses can improve cancer patients’ quality of life and satisfaction during treatment”  – Abstract 231P_PR - Impact of the continuity of nursing care delivered by a pivot nurse in oncology on improving satisfaction and quality of life of patients with advanced lung cancer - Elie Kassouf et al., under embargo until Thursday, 12 April 2018 at 12:30 CEST (Central European Summer Time)

Embargo Policy 
Abstracts accepted for presentation and for publication in the ELCC 2018 Abstract Book will be published online on the ELCC 2018 section of the ESMO website on Wednesday, 4 April 2018 12:00 (CEST)

Late Breaking Abstracts (LBA) will be published online at the beginning of the scientific session during which they are presented.

Journalists are required to observe embargoes as indicated, thank you!

Media registration

Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card. Media representatives are required to observe and abide by the ELCC Media Policy
To register for the event, please fill out the Complimentary Media Registration Form
Media registration in advance is strongly recommended, although on-site registration will still be possible.
Registered journalists can access all Congress sessions and the ELCC Press Room.

The ELCC Press Office staff will be available onsite to facilitate journalist’s work.

We look forward to welcoming you in Geneva

For further information please contact

ELCC Press Office - media@esmo.org


30 Route François-Peyrot
1218 Le Grand-Saconnex
Geneva, Switzerland

About the European Society for Medical Oncology (ESMO)

ESMO is the leading professional organisation for medical oncology. With 18,000 members representing oncology professionals from over 150 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.
ESMO’s educational resources support an integrated, multi-professional approach to cancer care. We have European roots and a global reach: we welcome oncology professionals from around the world and we seek to erase boundaries in cancer care as we pursue our mission across oncology, worldwide.

About the International Association for the Study of Lung Cancer (IASLC)

The International Association for the Study of Lung Cancer (IASLC) is the only global organisation dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information and follow them on Twitter @IASLC.

Last update: 20 Mar 2018

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.